Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 323

Next Previous
X
Search
Drug Profile

BNT 323

Alternative Names: BNT-323; DB-1303

Latest Information Update: 04 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duality Biologics
  • Developer BioNTech; Duality Biologics
  • Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer; HER2 positive breast cancer
  • Phase I/II Solid tumours
  • Clinical Phase Unknown Endometrial cancer

Most Recent Events

  • 01 Apr 2024 BioNTech plans a phase III trial for Endometrial cancer (Second-line therapy or greater, Recurrent) (IV, Infusion) (NCT06340568)
  • 20 Mar 2024 Clinical trials in Endometrial cancer (IV)
  • 20 Mar 2024 BioNTech plans additional trials with registrational potential in 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top